Invesco Ltd. Buys 1,811,757 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Invesco Ltd. increased its holdings in Cellebrite DI Ltd. by 122.1% in the first quarter, now owning approximately 3.3 million shares valued at about $64 million.
• Cellebrite DI recently reported $113.28 million in revenue for the quarter, exceeding analysts' expectations, and achieved an earnings per share (EPS) of $0.12, beating predictions by $0.01.
• Multiple analysts have adjusted their price ratings for Cellebrite DI, with the average price target lowered to $22.40, while maintaining a consensus rating of "Buy."

Invesco Ltd. increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 122.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,296,079 shares of the company's stock after purchasing an additional 1,811,757 shares during the quarter. Invesco Ltd. owned 1.38% of Cellebrite DI worth $64,043,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bosun Asset Management LLC boosted its holdings in Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after purchasing an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC boosted its stake in shares of Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after acquiring an additional 688 shares during the last quarter. TD Waterhouse Canada Inc. boosted its stake in shares of Cellebrite DI by 1.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after acquiring an additional 859 shares during the last quarter. Assetmark Inc. purchased a new position in shares of Cellebrite DI during the 1st quarter worth $33,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Cellebrite DI during the 1st quarter worth $51,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Up 2.8%

Shares of CLBT traded up $0.43 during trading hours on Thursday, reaching $15.91. 1,636,433 shares of the stock traded hands, compared to its average volume of 2,296,445. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30. The company's 50-day moving average price is $14.94 and its two-hundred day moving average price is $17.59. The company has a market cap of $3.81 billion, a P/E ratio of -20.93, a price-to-earnings-growth ratio of 3.07 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same quarter in the previous year, the company earned $0.10 EPS. Cellebrite DI's revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

CLBT has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Lake Street Capital dropped their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Finally, Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.